Should I buy or sell Ikena Oncology stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IKNA shares. View IKNA analyst ratings or view top-rated stocks .

What is Ikena Oncology's stock price target for 2024?

3 equities research analysts have issued 12 month target prices for Ikena Oncology's stock. Their IKNA share price targets range from $8.00 to $11.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 642.2% from the stock's current price. View analysts price targets for IKNA or view top-rated stocks among Wall Street analysts .

How have IKNA shares performed in 2024?

Ikena Oncology's stock was trading at $1.97 on January 1st, 2024. Since then, IKNA stock has decreased by 35.0% and is now trading at $1.28. View the best growth stocks for 2024 here .

When is Ikena Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our IKNA earnings forecast .

How were Ikena Oncology's earnings last quarter?

Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.41) EPS for the quarter, meeting the consensus estimate of ($0.41). The firm earned $0.66 million during the quarter, compared to analyst estimates of $2.39 million.

When did Ikena Oncology IPO?

Ikena Oncology (IKNA) raised $125 million in an initial public offering on Friday, March 26th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair acted as the underwriters for the IPO.

How do I buy shares of Ikena Oncology?

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IKNA

Ikena Oncology (IKNA) Stock Price, News & Analysis

→ The #1 Crypto for 2024 (From InvestorPlace) (Ad)

Free IKNA Stock Alerts

$1.28

+0.02 (+1.59%)

(As of 03:40 PM ET)

Compare

Today's Range: $1.25
▼
$1.30
50-Day Range: $1.24
▼
$1.60
52-Week Range: $1.02
▼
$7.64

Volume: 271,916 shs
Average Volume: 375,061 shs
Market Capitalization: $61.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Get Ikena Oncology alerts:

Ikena Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 642.2% Upside
$9.50 Price Target
Short Interest: Healthy
4.97% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.50) to ($1.31) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

607th out of 918 stocks

Biological Products, Except Diagnostic Industry

99th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
Ikena Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ikena Oncology has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.97% of the float of Ikena Oncology has been sold short.
Short Interest Ratio / Days to Cover
Ikena Oncology has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ikena Oncology has recently increased by 11.61%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ikena Oncology does not currently pay a dividend.
Dividend Growth
Ikena Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IKNA.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Ikena Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ikena Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.95% of the stock of Ikena Oncology is held by insiders.
Percentage Held by Institutions
75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ikena Oncology are expected to grow in the coming year, from ($1.50) to ($1.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ikena Oncology is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ikena Oncology is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ikena Oncology has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

Get His #1 Coin For 2024 FREE By Clicking Here

About Ikena Oncology Stock (NASDAQ:IKNA)

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

IKNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IKNA Stock News Headlines

April 10, 2024 | globenewswire.com

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

March 19, 2024 | markets.businessinsider.com

The Analyst Landscape: 4 Takes On Ikena Oncology

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 14, 2024 | finance.yahoo.com

Ikena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 13, 2024 | markets.businessinsider.com

Ikena Oncology’s Promising Drug Pipeline Merits a Buy Rating

March 12, 2024 | benzinga.com

Ikena Oncology: Q4 Earnings Insights

March 12, 2024 | finanznachrichten.de

Ikena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024 | globenewswire.com

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 27, 2024 | globenewswire.com

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

February 21, 2024 | finance.yahoo.com

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

February 21, 2024 | globenewswire.com

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

February 14, 2024 | finance.yahoo.com

Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

January 24, 2024 | finance.yahoo.com

Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

January 22, 2024 | investing.com

Ikena Oncology Inc (IKNA)

January 20, 2024 | benzinga.com

Ikena Oncology Stock (NASDAQ:IKNA) Dividends: History, Yield and Dates

January 19, 2024 | markets.businessinsider.com

Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes

January 19, 2024 | finanznachrichten.de

Ikena Oncology, Inc.: Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

January 18, 2024 | msn.com

Ikena to cut 35% of workforce, extend cash runway into 2H 2026

January 18, 2024 | finance.yahoo.com

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

November 11, 2023 | benzinga.com

Ikena Oncology Stock (NASDAQ:IKNA) Earnings Dates and Earning Calls

November 11, 2023 | morningstar.com

Ikena Oncology Inc IKNA

November 10, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Adicet Bio (ACET), Biogen (BIIB) and Ikena Oncology (IKNA)

November 10, 2023 | finance.yahoo.com

Broker Revenue Forecasts For Ikena Oncology, Inc. (NASDAQ:IKNA) Are Surging Higher

November 9, 2023 | marketwatch.com

Ikena Oncology Shares Slump to All-Time Low After IK-930 Cancer Drug Data

November 9, 2023 | msn.com

Ikena tumbles after early data for lead asset, Q3 financials

November 9, 2023 | benzinga.com

Why Is Cancer Firm Ikena Oncology Stock Trading Lower Today?

See More Headlines

Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IKNA
CUSIP: N/A
CIK: 1835579
Web: ikenaoncology.com
Phone: 857-273-8343
Fax: N/A
Employees: 43
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.50
High Stock Price Target: $11.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +654.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-68,170,000.00
Net Margins: N/A
Pretax Margin: -745.94%
Return on Equity: -44.21%
Return on Assets: -37.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.58
Quick Ratio: 12.58

Sales & Book Value

Annual Sales: $9.16 million
Price / Sales: 6.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.52 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 48,260,000
Free Float: 45,387,000
Market Cap: $60.81 million
Optionable: Not Optionable
Beta: 0.33

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Mark Manfredi Ph.D. (Age 53)
President, CEO & Director
Comp: $803.9k
Dr. Jotin Marango M.D. (Age 45)
Ph.D., CFO & Head of Corporate Development
Comp: $581.42k
Mr. Bob Lally
Senior Vice President of Finance & Operations
Ms. Srividya Subramanian Esq.
Ph.D., VP & Deputy General Counsel
Ms. Samantha Vuksanic
Head of Human Resources
Mr. Jeffrey Ecsedy Ph.D. (Age 54)
Chief Development Officer
Mr. Navin Parwani M.S.
VP & Head of Quality
Mr. David Damphousse M.S.
Senior Vice President of Clinical Development Operations
Dr. Caroline Germa M.D. (Age 51)
Chief Medical Officer
Mr. Valdas Jurkauskas Ph.D.
Senior Vice President of Technical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IKNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ikena Oncology stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ikena Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IKNA shares.
View IKNA analyst ratings or view top-rated stocks.
What is Ikena Oncology's stock price target for 2024?: 3 equities research analysts have issued 12 month target prices for Ikena Oncology's stock. Their IKNA share price targets range from $8.00 to $11.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 642.2% from the stock's current price.
View analysts price targets for IKNA or view top-rated stocks among Wall Street analysts.
How have IKNA shares performed in 2024?: Ikena Oncology's stock was trading at $1.97 on January 1st, 2024. Since then, IKNA stock has decreased by 35.0% and is now trading at $1.28.
View the best growth stocks for 2024 here.
When is Ikena Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our IKNA earnings forecast.

How were Ikena Oncology's earnings last quarter?: Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.41) EPS for the quarter, meeting the consensus estimate of ($0.41). The firm earned $0.66 million during the quarter, compared to analyst estimates of $2.39 million.
When did Ikena Oncology IPO?: Ikena Oncology (IKNA) raised $125 million in an initial public offering on Friday, March 26th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair acted as the underwriters for the IPO.
How do I buy shares of Ikena Oncology?: Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IKNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial